RAC1—along with SEC13, ARRB1 and ESR1, which we have already described—highlights the impairment of the beta-amyloid clearance in AD patients in which the neurotoxicity mediated by the beta-amyloid plaques is already high. Here, SEC13 is linked to Alzheimer disease.